ACTRN12613000590763
Completed
Not Applicable
To explore safety, feasibility and acceptability of mobile teledermoscopy for Queensland residents 50-64 years at high risk for melanoma.
Queensland University of Technology (QUT), Institute of Health and Biomedical Innovation (IHBI)0 sites50 target enrollmentMay 24, 2013
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Skin CancerMelanoma
- Sponsor
- Queensland University of Technology (QUT), Institute of Health and Biomedical Innovation (IHBI)
- Enrollment
- 50
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Inclusion criteria include: Male and female between 50\-64 years of age in Queensland. Previous melanoma or skin cancer diagnosis, fair skin or high number of moles. In addition, stratified sampling will ascertain that 50% of participants will have a history of checking their own skin, whilst the other 50% will have no record of SSE. All participants must be able to speak English to give informed consent. Participants must have access to a smartphone.
Exclusion Criteria
- •People who do not have access to an iPhone, People who have cognitive impairment that prevents them from providing informed consent, People who do not speak English for informed consent, those living outside of Queensland and not available for a visit to QUT for a skin exam.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Phase 1
Treatment Resistant Depression Intervention with Psilocybin-assisted PsychotherapyTreatment Resistant DepressionMental Health - DepressionACTRN12623000832673St. Vincent's Hospital, Sydney20
Not yet recruiting
Phase 4
Transplantation and Diabetes (Transdiab): A Pilot Randomised Controlled Trial of Metformin in pre-diabetes after kidney transplantatioew onset diabetes after kidney transplantatonNew onset diabetes after kidney transplantatonRenal and Urogenital - Kidney diseaseMetabolic and Endocrine - DiabetesACTRN12614001171606Auckland District Health Board200
Not yet recruiting
Not Applicable
Safety and Efficacy of Glucagon-like peptide 1 agonists in dialysis patientsEnd stage kidney diseaseDiabetesRenal and Urogenital - Kidney diseaseMetabolic and Endocrine - DiabetesACTRN12623000862640Auckland City Hospital95
Recruiting
Not Applicable
Safety and efficacy of biodegradable biliary and pancreatic stentsBiliary anastomotic strictureHepatico-jejunal stricturePost-ERCP pancreatitisOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonACTRN12621001534875Royal Prince Alfred Hospital60
Active, not recruiting
Phase 1
Evaluation of safety, feasibility and preliminary efficacy of MSCs from third party donors in the treatment of patients with osteonecrosis of the femoral head after allogeneic Stem Cell TransplantatioEUCTR2018-000886-35-ESEnrique Gomez-Barrena7